Theriva Biologics Reported The Out-licensing Of SYN-020, To Rasayana Therapeutics, Inc., A Privately-held Company Targeting The Gut-organ Axis Biology To Discover And Deliver Transformative Gut-targeted Medicines For Patients With Chronic Inflammatory Diseases